Clinical Trial: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Brief Summary: This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Detailed Summary:
Sponsor: Acerta Pharma BV
Current Primary Outcome: Determine the Maximum Tolerated Dose [ Time Frame: Cycle 1 (28 Days) ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Acerta Pharma BV
Dates:
Date Received: January 6, 2014
Date Started: January 2014
Date Completion:
Last Updated: December 14, 2016
Last Verified: December 2016